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AbstrAct
Androgen receptor (AR) signaling in stromal cells is important in prostate 
cancer, yet the mechanisms underpinning stromal AR contribution to disease 
development and progression remain unclear. Using patient-matched benign and 
malignant prostate samples, we show a significant association between low AR levels 
in cancer associated stroma and increased prostate cancer-related death at one, 
three and five years post-diganosis, and in tissue recombination models with primary 
prostate cancer cells that low stromal AR decreases castration-induced apoptosis. 
AR-regulation was found to be different in primary human fibroblasts isolated from 
adjacent to cancerous and non-cancerous prostate epithelia, and to represent altered 
activation of myofibroblast pathways involved in cell cycle, adhesion, migration, and 
the extracellular matrix (ECM). Without AR signaling, the fibroblast-derived ECM 
loses the capacity to promote attachment of both myofibroblasts and cancer cells, 
is less able to prevent cell-matrix disruption, and is less likely to impede cancer cell 
invasion. AR signaling in prostate cancer stroma appears therefore to alter patient 
outcome by maintaining an ECM microenvironment inhibitory to cancer cell invasion. 
This paper provides comprehensive insight into AR signaling in the non-epithelial 
prostate microenvironment, and a resource from which the prognostic and therapeutic 
implications of stromal AR levels can be further explored.
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INtrODUctION
Prostate cancer causes more than 28,000 deaths 
each year in the United States [1]. Critically, 10-33% 
of clinically localized cancers treated by surgery will 
eventually progress, indicative of undetected pre-
existing metastatic disease [2, 3]. Although epithelial 
differentiation scored by Gleason pathology at diagnosis 
aids in prognosis and management, it is imprecise in 
prediction of sub-clinical metastases or low grade tumors 
at risk of rapid progression. Recent studies of various solid 
tumors suggest that the stromal microenvironment may 
yield additional diagnostic information and novel avenues 
for therapeutic intervention [4-7].
Prostate development and homeostasis requires 
bidirectional signaling between epithelial cells and stromal 
constituents, including fibroblast and smooth muscle 
cells, vasculature, soluble factors and extracellular matrix 
(ECM) proteins. This signaling is disrupted in cancer 
[8-10], where the stroma becomes disorganized, normal 
non-malignant prostatic fibroblasts (NPFs) are replaced 
by activated cancer-associated fibroblasts (CAFs), and 
the composition of the ECM is altered [11-14]. Compared 
to NPFs, CAFs exhibit increased proliferation and 
migratory behavior [15], induce malignancy in non-
tumorigenic prostate epithelial cells [16-18], and provoke 
tumor progression via secretion of signaling factors [19-
22]. Moreover, genomic-level studies have identified 
prognostic CAF-specific gene signatures in digestive, 
non-small cell lung, breast and prostate cancers [4, 23-25].
In the adult prostate, activation of epithelial 
androgen receptor (AR) by testosterone (T) and 
5α-dihydrotestosterone (DHT) is necessary for cell 
survival and regulation of seminal fluid proteins including 
prostate specific antigen (PSA) [26], which is used 
clinically for tumour detection and monitoring. Although 
targeting androgens through ablation is therefore an 
effective initial treatment strategy for advanced cancer, 
most reoccur by refractory reactivation of epithelial AR 
[27-29]. In prostate development however, it is the stromal 
AR that is necessary for establishment of normal prostatic 
architecture, and for epithelial differentiation and function 
[30]. Decreased stromal AR expression in cancer has been 
associated with tumor resistance to androgen deprivation 
[31], and with relapse and progression following radical 
prostatectomy [25, 32, 33]. Currently however, we do not 
know how decreased stromal AR contributes to prostate 
cancer progression, or indeed how androgen action differs 
between prostate stromal and epithelial cells.
In this study, we compared AR levels in epithelial 
and stromal compartments of patient-matched benign 
and malignant prostate tissue, and demonstrate an 
association between low stromal AR levels and death 
from prostate cancer at one, three and five years post 
diagnosis. This is the first time that stromal AR changes 
have been shown to be specific to the immediate cancer 
microenvironment and not due to differences between 
patients, and are related to adjacent malignant but not 
benign regions of the same prostate. We further show that 
androgen signaling in human prostatic myofibroblasts 
induces a microenvironment inhibitory to the movement 
and invasion of tumor cells, primarily by altering ECM 
composition. This protective AR-mediated phenotype in 
prostate cancer-associated stroma has implications for 
understanding the early stages of cancer progression, 
and for the use of androgen withdrawal in the absence of 
surgical management.
rEsULts
Association of Ar levels in epithelium and stroma 
of benign and malignant prostate tissue with 
clinical parameters
The relationship between prostate cancer outcome 
and AR levels in stroma and epithelium was investigated 
by AR immunohistochemistry on 64 patient-matched 
BPH and prostate cancer samples in patients of median 
age 87 years (Fig. 1A). Similar to a previous report [33], 
the median intensity of AR staining was lower in stroma 
than in epithelia (Fig 1A, B). Median AR levels were 
similar in malignant and benign epithelia, but were lower 
in cancer-associated compared to benign stroma (p=4.1 
× 10-8, Fig. 1B, Table 1A). Consistent with established 
clinical associations, patients with higher Gleason score 
had a greater extent of disease, higher serum PSA levels, 
and were more likely to have died from their disease at 
censure. Additionally, a positive association between 
serum PSA levels was observed for AR content in cancer 
epithelia (p=0.004), but not with the other AR measures 
(Supplementary Fig. S1A-D). Higher Gleason score 
was associated with a higher median AR level in cancer 
epithelia (p<0.05) and lower AR in cancer-associated 
stroma (p<0.05; Fig.1C, Table 1A). Previous studies 
have reported an association between low stromal AR 
levels and biochemical recurrence [25, 32-34]. Here we 
assessed stromal and epithelial AR levels in paired BPH 
and cancer samples from the same patients, allowing 
discrimination of changes specific to cancer stroma from 
those related to an individual patient or prostate. Critically, 
we observed that low AR levels in cancer stroma, but 
not BPH stroma, were associated with prostate cancer 
related death (p=0.02; Table 1A) at censure, which was 
a minimum five years post initial diagnosis. The level of 
AR in cancer or BPH epithelia was not associated with 
outcome. We next dichotomized the cohort by median 
AR level in cancer epithelia or cancer stroma. High 
epithelial AR levels was associated with the extent of 
disease, Gleason score and serum PSA (p<0.05), but not 
with outcome (Table 1B). Conversely, low AR in cancer 
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stroma was associated with more extensive disease, and 
a greater risk of prostate cancer-related death (p<0.05, 
Table 1B). At the time of censure, the median prostate 
cancer specific survival for patients with low stromal AR 
was 622 days, which was significantly less than patients 
with high stromal AR expression at 2528 days (p=0.013). 
Finally, we observed lower 1, 3, and 5 year prostate cancer 
specific survival in patients with low stromal AR (30% at 
5 years) compared to high stromal AR (56% at 5 years; 
Table 1B). Despite AR in epithelial cells being more 
related to clinical parameters of histologically aggressive 
disease, our data suggest the intriguing possibility that 
AR in fibroblasts plays a more critical role in protecting 
against prostate cancer progression. Moreover, AR level 
in BPH stroma from the same patients was not associated 
with progression, supporting the existence of pathological 
cancer associated stroma in prostate cancer.
Myofibroblast AR expression modulates patient 
cancer cell response to castration in a tissue 
recombination model
To investigate the role of stromal AR in cancer, we 
utilized in vivo tissue recombination [35]. Human prostate 
cancer tissues obtained from four patients with moderate 
(Gleason 7) tumors were combined as heterotypic 
recombinants with AR positive human prostate PShTert-
AR myofibroblasts or AR negative PShTert-ctrl and sub-
renally grafted into immunodeficient NOD-SCID mice. 
Human cancer cells combined with both PShTert-AR and 
PShTert-controls formed phenotypically similar ductal 
structures that stained positive for the human-specific 
epithelial marker p63/CK8.18 (Fig. 2A). The survival 
of cancer foci, detected as p63-/CK8.18+, was similar 
in grafts from the four patients with PShTert-AR (65%, 
11/17) and PShTert-ctrl (56%, 13/23) lines. As expected, 
a significantly lower proportion of stroma in the grafts 
containing PShTert-ctrl myofibroblasts expressed AR 
(p<0.01; Supplementary Fig. 1E), with residual stromal 
AR expression arising from mouse-derived stroma. 
Castration resulted in significantly reduced tumor cell 
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proliferation in both PShTert-AR (p<0.01; Fig. 2B) and 
PShTert-ctrl myofibroblast (p<0.001; Fig. 2B) grafts, a 
reduction in cancer p63-/CK8.18+ foci (Fig. 2C), and a 
higher percentage of apoptotic cancer cells (caspase-3 
positive; p<0.001; Fig. 2D). More importantly, there 
was significantly less cancer cell apoptosis in grafts with 
PShTert-ctrl cells in comparison to grafts with PShTert-
AR cells (p<0.05; Fig. 2D). This latter result suggests that 
low stromal AR reduces apoptosis of primary cancer cells 
in response to androgen deprivation in vivo.
transcription activity, gene regulation, chromatin 
targeting and proliferation of prostate epithelial 
and myofibroblast cells diverge in response to 
androgens
We next sought to define the molecular actions of 
AR in PShTert-AR myofibroblasts, and to contrast those 
from androgen responses of prostate cancer epithelial 
C4-2B cells. These lines have a comparable levels of 
AR protein (Fig. 3A), and both have a functional AR 
signaling pathway as demonstrated by increased FKBP5 
protein levels and probasin reporter (PB3) transactivation 
in response to DHT (Fig. 3A, Supplementary Fig. S2A). 
These responses are AR specific, and could be blocked 
by the AR antagonist, BIC (Fig. 3A, Supplementary Fig. 
S2A). Transcriptional reporter assays suggest however, 
that the DHT response of AR is 10-fold less sensitive in 
myofibroblasts than in epithelia (Supplementary Fig. S2B), 
and is not due to technical limitations such as reporter level 
(Supplementary Fig. S2C). Furthermore, only classical 
androgen agonists (DHT and T) and medroxyprogesterone 
acetate (MPA) could produce a transcriptional response 
in PShTert-AR cells (Supplementary Fig. S2D), compared 
with the expected broader ligand responses in C4-2B 
cells (Supplementary Fig. S2E). Nevertheless, the ability 
of the AR to stimulate a panel of AR-targeted reporters 
Figure 1: The expression of stromal AR is related to clinical parameters and outcomes of prostate cancer. A-c. Patient-
matched duplicate cores of BPH and cancer were immunostained with anti-AR antibody. Samples were scored by two independent 
researchers, using a scale of high (3), moderate (2), low (1) intensity or absent (0) immunostaining in the epithelia and stroma and averaged 
between the duplicate samples and scorers. b. Scores were evaluated in relation to disease state for stroma (St) and epithelia (Ep) and 
compared using the Wilcoxon Rank-Sum test c. Mean AR score ± SEM for both the cancer stroma (Ca-St) and epithelia (Ca-Ep) was 
calculated for each Gleason grade.
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was consistent between PShTert-AR and C4-2B cells 
(Supplementary Fig. S2F). 
In order to more precisely define the transcriptional 
role for AR in PShTert-AR cells, we performed expression 
microarray analysis, identifying 2615 DHT regulated 
genes in PShTert-AR myofibroblasts and 1000 in C4-2B 
epithelial cells (>0.5 log2 fold change). Importantly, only 
254 of those regulated genes were common between the 
two cell lines, and half of those (127/254) were regulated 
in the opposite direction (Fig. 3B). RT-qPCR analysis of an 
independent sample set confirmed the uniquely regulated 
(Fig 3C-D) and similarly regulated (Fig. 3E) responses 
to DHT in each cell line. The AR-specific nature of 
myofibroblast responses was confirmed by their absence in 
PShTert-ctrl cells (Supplementary Fig. S3). ChIP analysis 
of well-characterized androgen target genes suggests 
that divergent AR occupancy of promoters/enhancers is 
responsible for the cell-specific regulation by DHT (Fig. 
3F-H), consistent with a contemporary understanding of 
AR chromatin targeting [36]. We next applied pathway 
analysis to the top 1000 regulated genes in each cell line, 
which in PShTert-AR cells comprised 390 upregulated 
and 610 downregulated genes, and in C4-2B cells 648 
upregulated and 352 downregulated genes. DHT-treated 
myofibroblasts were enriched in adhesion and ECM 
organization, but depleted in cell cycle and migration 
(Supplementary Table 2). In contrast, DHT in C4-2B 
cells drives processes of lipid and fatty acid synthesis and 
migration, and depletion of apoptosis (Supplementary 
Table 2). Importantly, a considerable number of pathways 
were regulated in opposite directions by DHT in epithelial 
and myofibroblast cells, despite limited commonality 
in regulated genes (Fig. 3B; Supplementary Table 2). 
Consistent with the divergent gene responses, DHT 
Figure 2: Loss of myofibroblast AR protects cancerous prostatic epithelia from castration induced apoptosis. Tissue 
recombination of patient prostate cancer tissues co-grafted with either PShTert-AR or PShTert-ctrl myofibroblasts into immune-deficient 
host mice. After 8 weeks, host mice were castrated for a further three days. A. Human tissue was identified by dual immunostaining of 
basal cell marker p63 (brown stain) and epithelial marker CK8/18 (pink stain); cancer foci were p63-CK8/18+ highlighted by white outline. 
AR levels were assessed in samples immunostained with anti-AR antibody. b. Epithelial proliferation was determined by the percentage of 
cells immunostained for anti-Ki-67. c. Human cancer tissue grafts from castrated mice was assessed for CK8/18, p63 and AR as described 
in (A). D. Epithelial cell death was measured through cleaved caspase-3 immunostaining and percent positive cells counted (*, p<0.05, **, 
p<0.01, ***, p<0.001, Student’s T-test).
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stimulated C4-2B cells to proliferate as previously 
reported [37] (p<0.05; Fig. 4A), but inhibited PShTert-AR 
growth in a dose-dependent manner (p<0.001, Fig. 4B). 
Cell death did not vary significantly between treatments in 
C4-2Bs over the 6 day period, but was significantly altered 
by all doses of DHT in PShTert-AR cells at days 3 and 4 
(p<0.05; 5-20% of viable cells; Supplementary Fig. S4). 
Importantly, BIC reversed these effects, confirming AR 
mediation of the divergent growth responses (Fig. 4A, B; 
right panels). 
One mediator of the anti-proliferative effect of 
androgen in myofibroblasts may be the fibroblast-specific 
androgen regulated F-box protein 32 (FBXO32) gene 
product. FBXO32 is a member of the family of DNA-
licensing proteins that regulates progression from G1 
phase by inhibiting cyclin D1 [38]. To determine whether 
FBXO32 could regulate proliferation in AR expressing 
myofibroblasts, we used siRNA knockdown (Fig. 4C). 
FBXO32 depletion partially reversed the inhibitory effect 
of DHT on myofibroblast cell growth over the course of 
a five day period (p<0.05; Fig. 4D). Together, the above 
results demonstrate that AR in epithelial and myofibroblast 
lineages plays distinct roles, one of which is to direct 
divergent proliferative responses to DHT.
AR action in myofibroblasts promotes epithelial 
cancer proliferation
We next considered whether AR activity in 
myofibroblasts could affect epithelial growth. Conditioned 
media was collected from PShTert-AR and PShTert-ctrl 
myofibroblasts treated with or without DHT. Compared 
to vehicle, media from DHT treated AR positive 
myofibroblasts increased C4-2B and PC-3 proliferation 
by 1.64 and 2.72 fold respectively (p<0.05, Fig. 4E, F). 
Figure 3: Cell specificity of AR action may be mediated by interactions of AR with DNA. A. Lysates from C4-2B and 
PShTert-AR cells treated with or without 10 nM DHT and 10 µM bicalutamide (BIC) were probed for AR and FKBP5. b. Affymetrix 1.0st 
Gene Array of 10 nM DHT or vehicle control (V.C.) treated PShTert-AR or C4-2B cells, presented as a Venn-diagram of genes with >0.5 
log2 fold change in expression between treatments. c-E. Microarray was validated via RT-qPCR of independent samples produced under 
the same conditions. Data is represented as mean + SEM of triplicate biological replicates (V.C. vs DHT * p<0.05, ** p<0.01, ***p<0.001 
Student’s T-test). F-H. Chromatin immunoprecipitation (ChIP) was performed on C4-2B and PShTert-AR cells treated with 10 nM DHT 
or vehicle, and immunoprecipitated with anti-AR N20 or nonspecific IgG antibody. ChIP samples were quantified by RT-qPCR and mean 
percent input for each binding region in the proximity of (F) FBXO32, (G) PSA and (H) FKBP5 was normalized to a non-specific binding 
region.
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Figure 4: C4-2B and PShTert-AR cells have different proliferative responses to DHT. A-b. Proliferative response of C4-2B 
and PShTert-AR cells to 10 nM DHT was measured daily via Trypan blue exclusion assays. c,D. The androgen mediated gene and DNA-
licensing factor, FBXO32, was silenced via siRNA (c) and the effect on PShTert-AR growth in response to 10 nM DHT was measured via 
Trypan blue exclusion assay (D). E,F. The effect of conditioned media from PShTert-AR and PShTert-ctrl on C4-2B and PC-3 cells was 
measured as in A. Data represents the mean number of viable cells in triplicate wells ± SEM. G,H. The presence of DHT in the conditioned 
media was assessed via transactivation assays performed on C4-2B (G) and PShTert-AR (H) cells. Data presented as mean relative light 
units (RLU) ± SEM of six independently transfected wells.
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Media from DHT treated AR negative myofibroblasts 
did not alter the proliferative response of either epithelial 
line. The addition of DHT to vehicle conditioned media 
from PShTert-AR cells enhanced proliferation of C4-
2B but not AR negative PC-3 cells, an effect reversed 
by co-treatment with BIC (Fig. 4E, F). In contrast, DHT 
supplementation had no effect on the higher proliferation 
seen with DHT stimulated myofibroblast conditioned 
media (Fig. 4E, F). Residual DHT from the conditioning 
process was not responsible for these effects, as high-
sensitivity transcriptional reporter assays did not reveal 
any androgen activity in conditioned media (Fig. 4G, H). 
It appears likely from these studies that DHT stimulation 
of AR positive myofibroblasts produces secreted, soluble 
factors that are pro-proliferative to epithelial cells.
AR action in prostate myofibroblast cells controls 
adherence of myofibroblast cells
As pathways involving adhesion were highly 
enriched in DHT treated myofibroblasts, we next assessed 
whether this translated to altered attachment. Treatment 
with DHT had no effect on trypsinization of C4-2B cells 
or PShTert-ctrl cells, but increased retention of PShTert-
Figure 5: DHT has pro-adherent effects on fast and long term adherence of myofibroblast cells. A-c. The quantity of C4-
2B, PShTert-ctrl, and PShTert-AR cells, treated with 10 nM DHT or equivalent vehicle (V.C.), remaining after trypsinization over 15 min 
was measured using crystal violet staining. Presented as mean ± SEM of six technical replicates, and representative of three independent 
experiments. D,E. Adherence was measured by manually counting the number of 10 nM DHT, V.C. or 10 µM bicalutamide (BIC) treated 
C4-2B, PShTert-ctrl, and PShTert-AR cells adhering after 30 min. Data is presented as mean ± SEM of four samples and is representative of 
three independent experiments. (* p<0.05 V.C. vs DHT, # p<0.05 DHT vs DHT+BIC Student’s T-test). F,G. PShTert-AR cells transfected 
with siRNA against Hic-5 or scrambled control were assayed for adherence as described in D but measured over a 2 h period. Data is 
presented as mean ± SEM of four replicates and representative of three independent experiments. H-I. Hic-5 contribution to androgen-
mediated attachment was assayed as described in A-C. For all time course adherence data, significance (p<0.05) was determined by one-
way ANOVA.
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AR cells by 25.1 ± 3.6% to 44.7 ± 1.8% (p<0.0001, Fig. 
5A-C). This response was DHT dose dependent and 
reversible by BIC (p<0.05; Supplementary Fig. S5), 
thus demonstrating AR involvement. Furthermore, DHT 
treatment significantly increased attachment of PShTert-
AR cells by 33-44% at 30 min in a dose-dependent 
manner, suggestive of an additional non-genomic effect 
(p<0.05, Fig. 5D, E). This response was measurable for 
4 h and could be reversed by BIC (Fig. 5D), but did not 
occur with either C4-2B or PShTert-ctrl cells. 
We recently reported that hydrogen peroxide-
inducible gene 5 (Hic-5/TGFB1I1), a predominantly 
fibroblast-specific AR coregulator and a component of the 
focal adhesion (FA) complex, plays an important role in 
AR-mediated activity in myofibroblasts [39-41]. To assess 
whether Hic-5 might be involved in DHT/AR-mediated 
adherence, we utilized siRNA knockdown in PShTert-
AR cells (Supplementary Fig. S6). Compared to negative 
siRNA control, depletion of Hic-5 abolished the effect of 
DHT on myofibroblast adherence (Fig. 5F, G). Similarly, 
Hic-5 knockdown eliminated the positive effect of DHT 
pretreatment on myofibroblast attachment (Fig. 5 H, I). 
AR however retained the capacity to regulate FKBP5 
expression when Hic-5 was depleted, implying that 
decreased adherence was not due to absolute loss of AR 
activity (Supplementary Fig. S6). Together, these results 
suggest an active role for AR in myofibroblast attachment, 
mediated via cellular interactions with a known AR 
coregulator.
AR action in prostate myofibroblasts alters the 
EcM to increase cancer cell attachment and 
decrease cancer cell migration and invasion
As we had observed increased attachment and 
altered expression of ECM components with DHT 
treatment in the myofibroblast cells (Supplementary 
Table 2), we next measured adherence of epithelial cells 
to the myofibroblast-deposited matrix. PC-3 attachment 
to matrix generated by DHT treated PShTert-AR cells 
was increased 31 ± 12% over matrix from vehicle treated 
cells, and could be inhibited by BIC (p<0.05, Fig. 6A). 
In contrast, PC-3 adhesion to matrix from PShTert-ctrl 
cells was unaffected by ligand (Fig. 6A). Similarly, PC-3 
migration over ECM generated by DHT treated PShTert-
AR cells was significantly less than migration over ECM 
produced under vehicle control treatment after 7 (22±3% 
vs 30±3.5%) and 11 (1±1.3% vs 7±2.4%) hours (p<0.05, 
Fig 6B, Supplementary Fig. S7). As previously reported, 
cancer cell migration was significantly faster over ECM 
than cancer cell migration over plastic alone [42]. We next 
assessed the adherence of cancer cells to a myofibroblast 
conditioned 3D-ECM as previously described [43]. 
Consistent with the above results, a significant increase 
in C4-2B attachment (Fig. 6C) and proliferation (Fig. 
6D) was only observed in gelatin conditioned by DHT-
treated PShTert-AR cells, but not with gelatin conditioned 
by vehicle-treated PShTert-AR cells, or with vehicle- or 
DHT-treated PShTert-ctrl line (Fig. 6C, D). We also 
identified a significant decrease in invasion of the cancer 
cells through DHT-treated PShTert-AR gelatin matrix 
in comparison to matrix conditioned by vehicle treated 
PShTert-AR or DHT-treated PShTert-ctrl cells (Fig. 6E). 
Candidate RT-qPCR analysis confirmed DHT 
upregulation of ECM proteins with adhesive properties 
(i.e. COL1A1, COL3A1, COL4A6, and FBN1), and 
inhibition of ECM degrading enzymes (i.e. MMP1; Fig. 
6F). Using ELISA, dose dependent DHT regulation 
of Collagen 1 protein was confirmed (p<0.05; Fig. 
6G). Significantly, in a set of human patient cancer-
adjacent, BPH, and normal fibroblasts (CAF, BAF, and 
NPF respectively) we observed increased expression of 
FBXO32 and COL4A6 genes when treated with DHT in 
CAFs and BAFs only (p<0.05, Fig. 6H), and a marked 
decrease in expression of MMP1 expression in all three 
cell types (p<0.05, Fig. 6I). Collectively, the above results 
suggest that stromal/fibroblast AR may act to alter the 
composition of the ECM, resulting in a pro-adhesive, anti-
migratory matrix.
DIscUssION
Extensive analyses of cancerous epithelia have 
failed to significantly improve prediction of pre-existing 
prostate metastases or subsequent progression [44]. 
However, it has been known for over a decade that the 
level of stromal AR is inversely related to Gleason 
score, response to therapy, metastasis and subsequent 
biochemical relapse [25, 31-34]. This is the first study 
to associate decreased stromal AR levels with increased 
prostate cancer-related death, even in the context of 
older patients with significant disease burden at the time 
of diagnosis and initial management. Importantly, this 
now establishes that there is no maximum age at which 
stromal AR content cannot provide additional prognostic 
information. Conversely, since Gleason score in our cohort 
was found to be related to traditional tumor characteristics 
of poor prognosis, such as serum PSA, cancer-related 
death and epithelial AR content, the stromal AR results are 
likely reflective of what also happens in younger patients. 
In addition to confirming a protective role for stromal AR 
against prostate cancer progression, our data suggest that 
analysis of stromal AR levels and/or function may provide 
useful information regarding tumor aggressiveness and/or 
early metastasis, and could guide clinical decision making 
in younger and older men alike. This is particularly 
important in the latter group where there is a pervasive 
belief that older men are more likely to die with prostate 
cancer than from it.
Metastasis of solid tumors is accomplished by 
either proteolytic migration, involving secretion of ECM 
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Figure 6: AR in cancer associated fibroblasts and model of AR action in prostate stroma. A. PC-3 attachment to ECM 
deposited by PShTert-ctrl and PShTert-AR cells treated with or without 10 nM DHT ± 10 µM BIC was measured as described in Fig. 5D. 
Data presented as mean adherence per mm2 of four wells ± SEM. (* p<0.05 vehicle control (V.C.) vs DHT, # p<0.05 DHT vs DHT+BIC 
Student T-test). b. Migration of PC-3 cells over matrices created from V.C. or DHT treated PShTert-AR myofibroblasts was assessed by 
measuring the area of the cell-free gap over a 15 hour time period and calculated as a percentage of time point 0. Data represents mean ± SEM 
of three replicates. c-E. PShTert-AR or PShTert-ctrl cells were grown to confluence on a gelatin layer and allowed to deposit a 3D-ECM 
for 8 d following 10 nM DHT or V.C. treatment before myofibroblast removal. c. Adherence of 5 × 104 C4-2B cells to the 3D-matrices 
was determined after an hour. Data is presented as mean ± SEM of four replicates and is representative of three independent experiments. 
D. The effect of the 3D-matrices on epithelial proliferation was determined via Trypan blue exclusion assay. Data is presented as mean 
± SEM of four replicates and is representative of three independent experiments. E. Invasion of calcein-labeled C4-2B cells through the 
myofibroblast 3D-matrices was determined via a modified Boyden chamber technique. Data is presented as mean ± SEM of six samples and 
is representative of three independent experiments. F. RT-qPCR analysis for expression of selected ECM genes in PShTert-AR cells. Data 
represents the mean + SEM from triplicate biological replicates. G. ELISA analysis of collagen-1 (COL1) levels in conditioned media from 
DHT treated PShTert-AR cells. Data is presented as the mean + SEM from six replicates representative of two independent experiments. 
H. RT-qPCR gene analysis in human patient cancer associated fibroblasts (CAF), BPH associated fibroblasts (BAF), and normal prostatic 
fibroblasts (NPFs), isolated and treated with either V.C. or 100 nM DHT. Data represents the mean of technical triplicates (± SEM) from 
N=1 for each cell type (in all panels * p<0.05, ***p<0.001, Student’s T-test). I. Model of AR action in prostate myofibroblasts. The AR 
signaling in myofibroblasts causes increased production of ECM components and inhibition of MMP enzymes. When AR signaling in 
myofibroblasts is lost, decreased expression of ECM components and enhanced MMP expression create an environment which decreases 
cancer cell attachment and increases cancer cell invasion.
Oncotarget16145www.impactjournals.com/oncotarget
degrading enzymes to create space into which cells 
move, and/or amoeboid (non-proteolytic) squeezing of 
cells through the ECM. The amount and arrangement of 
ECM fibers, enzymes, and ECM pore size are capable of 
altering each type of migration, and have been implicated 
in malignant disease [45-47], and studies of malignant 
ovarian and breast cancers have identified defects in matrix 
protein cross-linking that render ECM more susceptible to 
proteolytic degradation [48, 49]. We show here that AR 
action in myofibroblasts leads to decreased expression 
of enzymes involved in ECM digestion and increased 
expression of key components of the ECM, both in our 
model cell line and primary patient fibroblasts. These 
results are supported by our findings that AR positive 
myofibroblasts produce a more adhesive ECM when 
treated with DHT, which inhibits migration and provides a 
less invasive environment for prostate cancer cells. Further 
work will be required to distinguish the role of androgen 
regulation of matrix degrading proteases. Collectively, 
our data suggest that fibroblast AR may play a key role 
in regulating cell attachment, and in organization of the 
ECM, and that a loss of stromal AR creates a passive 
ECM environment that is less adhesive for cancer epithelia 
and more conducive for metastatic spread (Fig. 6H). We 
predict that defining the precise contribution that AR 
makes to ECM composition may inform on early disease 
spread and therefore overall patient outcome. 
It appears from our results and those of others that 
stromal AR may also promote prostate cancer proliferation, 
as suggested here by the production of an unidentified 
soluble mediator, and/or ECM-bound growth factor [50-
52]. On the surface, this appears at odds with clinical 
data demonstrating an association between low stromal 
AR and death from prostate cancer. Given decreased 
stromal AR expression throughout progression however 
[13, 50, 53, 54], or as shown here with increasing Gleason 
score, these two findings may not be as paradoxical 
as might be thought. Indeed, stromal AR may be pro-
proliferative in early prostate cancer; exogenous tumors 
in mice grow larger when associated with AR sensitive 
stroma [55], and are inhibited by stroma lacking AR [50]. 
Conversely in vivo knockdown of stromal AR was found 
to be more effective at inhibiting tumor growth in early 
stages of progression rather than at later stages [50, 56]. 
In this study, there was no difference between take rate or 
cellular morphology of human tumors grafted with either 
AR positive or AR negative myofibroblasts. Instead, we 
found in grafts containing AR positive myofibroblasts 
that cancer cells exhibit increased apoptosis following 
castration. Collectively, these findings suggest that stromal 
AR can play a pro-proliferative, pro-adhesive and/or anti-
migratory role in prostate cancer. It is entirely possible that 
stromal AR is pro-tumorigenic in very early stage disease, 
but prevents metastasis of evolving epithelial cancer cells 
by altering the composition and permissiveness of the 
ECM. 
In conclusion, this manuscript is the first to show 
that unique androgen/AR transcriptional responses in 
prostate myofibroblasts play an important role in stromal-
mediated alterations to the ECM and microenvironment. 
Clinically, it will be important to determine the key factors 
affected by a loss of stromal AR that may influence patient 
outcome and could be exploited by targeted therapies. The 
precise composition of the ECM may be one such key 
mediator of epithelial cancer cell invasiveness and thus 




The South Australia Prostate Cancer Clinical 
Outcomes Collaborative (SA-PCCOC; http://www.sa-
pccoc.com/) tracks men diagnosed with prostate cancer 
in the South Australian public health system. Using the 
SA-PCCOC database, we identified 66 sequential patients 
whom underwent TURP for symptomatic relief of BPH 
urinary obstruction at the Repatriation General Hospital 
(RGH; Daws Park, South Australia) between 2000 and 
2007, in which there was (i) a first diagnosis of prostate 
cancer on histological Gleason grading, (ii) cancer 
comprising >5% of the specimen, and (iii) sufficient areas 
of BPH and cancer in each sample from which multiple 
cores could be obtained. Areas of BPH and cancer were 
identified by H&E staining and mapped onto paraffin 
embedded material by a pathologist. Duplicate five mm 
cores of BPH and cancer from each individual were then 
used to generate tissue microarrays. Clinical data relating 
to each patient was acquired from the SA-PCCOC 
database. Sample and data acquisition was performed 
according to protocols approved by the Flinders Medical 
Centre and RGH Ethics Committees (Protocol #042/10). 
Immunohistochemistry was performed with the AR 
N-20 antisera (Santa Cruz Biotechnology) and, detected 
using the LSAB+ System-HRP kit (Dako Laboratories, 
CA, USA). Staining was scored additively by two 
researchers in three independent fields from 0 (no staining) 
to 3 (very intense staining), yielding sample scores of 0-9 
in epithelial and stromal compartments of both cancer 
and BPH. No stromal compartment achieved very intense 
staining. The mean sample score from the two researchers 
yielded the AR staining intensity score. Differences in 
staining intensity, Gleason Score, serum PSA and percent 
prostate cancer were assessed using two-tailed Mann-
Whitney U tests. In samples dichotomized by median AR 
level, differences in prostate cancer-specific death were 
assessed using Barnard’s Exact test. Significance was set 
at p<0.05.
Human tissue was obtained from consented patients 
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in accordance with Human Ethics Research Approvals 
34306 at Epworth Hospital, 03-14-04-08 at Cabrini 
Hospital and RMO 2006/61082004000145 at Monash 
University, and processed as previously published [18]. 
Briefly, tissue from patients with BPH or Gleason score 
7 prostate cancers were extracted from TURP and radical 
prostatectomy specimens respectively. Primary fibroblasts, 
representing CAFs, BAFs and NPFs were isolated from 
patient specimens, cultured in RPMI with 5% FCS and 
100nM testosterone or equivalent vehicle (ethanol), and 
assessed in vitro between passages 3-6. The integrity of 
primary fibroblast cultures was confirmed in vitro by 
growth properties, immunological markers and RNA 
expression, and their tumorigenic potential in vivo using 
tissue recombination with BPH-1 cells.
cell lines
For in vitro experiments C4-2B [57] and PC-3 
(ATCC, VA, USA) prostate cancer epithelial cells, 
telomerase immortalized human prostate stromal 
myofibroblast cells expressing AR (PshTertAR) or 
matched empty vector control (PShTert-ctrl) [31], and 
WMPY human prostate fibroblasts expressing Hic-5 or 
scrambled shRNA [58] were used. All cell lines were 
authenticated via Short Tandem Repeat testing in 2014, 
completed at CellBank Australia (NSW, Australia). In 
experimental conditions cells were incubated in stripped 
medium (Phenol Red Free-RPMI 1640 with 5% dextran 
coated (DCC) FBS) supplemented with 10 nM DHT or 
vehicle, or 10 µM bicalutamide (BIC). For conditioned 
media, confluent PShTert-AR and PShTert-ctrl cells were 
incubated in stripped medium (Phenol Red Free-RPMI 
1640 with 5% dextran coated (DCC) FBS) supplemented 
with 10 nM DHT or vehicle. Media was collected at 6, 12, 
18, 24, 36, or 48 h after initial treatment, centrifuged to 
remove debris, filtered and frozen, and subsequently used 
neat for transactivation assays or at a 1:1 dilution with 
fresh stripped media for other cell studies.
transactivation assays
Transactivation studies were performed as 
described previously [59] using Lipofectamine 2000™ 
(Life Technologies, CA, USA) or LTX-plus (Life 
Technologies) for transfection of luciferase constructs. 
Following transfection, cells were treated with 0.1-1000 
nM of steroids or equivalent vehicle (ethanol) control 
for 22 h. Results are presented as mean (± SEM) of six 
independently transfected wells.
chromatin immunoprecipitation (chIP)
ChIP was performed as described previously [59], 
using semi-confluent PShTert-AR or C4-2B cells were 
treated for 4 hours with 10nM DHT or vehicle. Cells were 
then formaldehyde fixed and sonicated to produce 300-
1500 bp fragments. Lysates were pre-cleared with yeast 
tRNA and protein G sepharose, and immunoprecipitated 
overnight with 4 µg of AR N-20 (Santa Cruz 
Biotechnology) or rabbit IgG (Santa Cruz Biotechnology) 
antiserum. Protein-DNA complexes were eluted from the 
beads, digested with proteinase K and was DNA purified 
by phenol-chloroform extraction. Resulting DNA samples 
were assessed by RT-qPCR in triplicate, with primers 
listed in Supplementary Table 1. Data was calculated 
as percent input and normalized to non-specific control 
(NC2). Results are representative of three independent 
experiments.
ELIsA
ELISA was used to measure collagen 1 levels 
in media collected from confluent PShTert-AR 
myofibroblasts treated with 50 µg/ml ascorbic acid 
(Sigma-Aldrich, NSW, Australia) and either DHT, vehicle 
control and or BIC. Media collected from six independent 
treated confluent cells was plated into 96-well Maxisorp 
(Nunc, Simga Aldrich) plates and incubated overnight at 
4oC. Plates were washed in PBS supplemented with 0.1% 
Tween (PBST), blocked in 2.5% BSA and washed in 
PBST, plates were probed with rabbit anti-collagen type 
1 antibody (0.25 µg/ml, Rockland Immunochemistry, PA, 
USA) for 3 h and detected via a europium-tagged anti-
rabbit secondary antibody. The concentration of collagen 
was subsequently fluorescently detected using 340 nm 
excitation/615 nm emission spectra.
tissue recombination 
Renal capsule tissue recombination grafting of 
PShTert-AR or PShTert-ctrl cells with pieces of patient-
derived primary human prostate cancer tissue into NOD-
SCID mice was performed and analyzed as previously 
described [18, 35, 60]. Briefly, PShTert-AR or PShTert-
ctrl cells (2.5 X 105) were combined with 2 mm X 2 
mm X 1 mm pieces of patient-derived primary human 
prostate cancer tissue in 30 µl of collagen/RPMI 1640 + 
5% FBS with 0.1% penicillin-streptomycin for 24 h, and 
grafted under the renal capsule of NOD-SCID mice for 8 
weeks. Mice were castrated, and grafts allowed to grow 
for an additional 3 days before being removed, paraffin-
embedded and sectioned. Immunohistochemistry for Ki-




RNA extracted from cells treated with either DHT 
or vehicle using the RNeasy Kit (Qiagen, Melbourne, 
Australia), was analyzed using Affymetrix 1.0st Gene 
Arrays. Data was Bioinformatically analyzed using either 
in R using Gene Ontology categories, or in R or using 
DAVID Bioinformatics Resources http://david.abcc.
ncifcrf.gov/home.jsp (46, 47). 
Quantitative real-time Pcr (rt-qPcr)
cDNA created from sample RNA was analyzed 
via RT-qPCR as previously described [61], using SYBR 
Green (Biorad) and primer pairs detailed in Supplementary 
Table 1. Data is presented relative to GAPDH, PPIA, 
and mRPL19 as per GeNorm (http://medgen.ugent.
be/~jvdesomp/genorm/#introduction).
Immunoblot
Protein lysates in RIPA buffer were prepared as 
previously described [59] and immunostained with anti-
AR (N20, Santa Cruz Biotechnology), anti-FKBP5 (H100, 
Santa Cruz Biotechnology), anti-alpha tubulin (05-829, 
Millipore, Bedford, MA), or anti-β-actin (A1978, Sigma-
Aldrich).
Proliferation, adhesion and motility
Proliferative response of PShTert-AR or C4-2B cells 
to DHT and or BIC was measured in quadruplicate via 
Trypan blue exclusion. Adhesion of PShTert-AR, PShTert-
ctrl, or C4-2B cells was measured using an adhesion assay 
as described previously [62]. Briefly, 5 X 104 PShTert-AR, 
PShTert-ctrl, or C4-2B cells were added to 24-well plates 
containing treatment media and left to adhere for 15-240 
min at 37oC. Media was removed and cells were washed 
with PBS before manual counting. Cellular attachment 
(trypsinization resistance) was measured using a crystal 
violet assay adapted from a previous study [62]. Briefly, 
PShTert-AR or C4-2B cells were plated in stripped media 
(5 X 104 cells/well in 96 well plates) overnight and 
treated with 1-100 nM DHT ± 10 µM BIC or equivalent 
vehicle control for 16 h. Cells were washed with PBS and 
incubated with trypsin for 2.5 - 15 min. Cells were washed, 
ethanol fixed and stained with 1% crystal violet solution. 
Dye was eluted from cells with 10% glacial acetic acid 
and the concentration measured at an absorbance of 595 
nm. Motility and invasion was tested described previously 
[63], using calcein labelled C4-2B cells were applied to 
modified Boyden chambers (ChemoTx, Neuro Probe). 
Calcein AM was measured in the bottom wells using a 
FLUOstar OPTIMA plate reader at 480 nm excitation and 
520 nm emission wavelengths.
Conditioned matrix
Matrices produced from confluent fibroblasts treated 
with 50 µg/ml ascorbic acid and 10 nM DHT or vehicle 
or 10µM BIC, were decellularized with EDTA and used in 
adhesion assays (above) and trypsinization assays adapted 
from previous descriptions [62]. 
3D-matrices
3D-matrices were produced from DHT or vehicle 
treated fibroblasts seeded into gelatin coated wells as 
previously described [43]. After decellularization with 
extraction buffer containing PBS, 0.28% ammonium 
hydroxide (Sigma-Aldrich), and 0.5% Triton-X (Sigma-
Aldrich), the remaining 3D-matrix was used for adherence, 
proliferation, invasion, and motility/gap closure assays.
When the cells had grown to 100% confluence, 
media was replaced with stripped media supplemented 
with 50 µg/ml ascorbic acid and 10 nM DHT or equivalent 
vehicle control. Treatment was repeated every 48 h. After 
8 days, myofibroblasts were removed via an extraction 
buffer containing PBS, 0.28% ammonium hydroxide 
(Sigma-Aldrich), and 0.5% Triton-X (Sigma-Aldrich). 
Remaining 3D matrix was gently washed in PBS prior to 
adherence, proliferation and invasion assays. 
For cancer cell gap closure assays, into each well, 
sterile silicon culture-inserts (Ibidi 80209) were positioned 
into wells containing 3-D matrices, and PC3 cells (3.5 x 
104 cells per chamber) in stripped medium were aliquoted. 
Following 16h by incubation, Ibidi inserts were removed, 
leaving a 500µm cell-free gap. Migration of PC3 cells 
across the gap was monitored for 0, 3, 7, 11, and 15 h 
time-points, using a Zeiss Axio Observer.Z1 with HBO 
100 microscope illuminating system (Zeiss, Göttingen, 
Germany). Migration was measuring as cell-free gap-
closure using AxioVision Rel 4.8 software, and analysed 
with the MRI Wound Healing Tool (ImageJ software, 
version 1.47v).
AcKNOWLEDGMENts
The authors would like to acknowledge the 
South Australian Prostate Cancer Clinical Outcomes 
Collaborative in cohort assembly and clinical data 
collation. Drs Claudine Bonder, Carmella Ricciardelli, and 
Margaret Centenera provided methodological assistance, 
Aleksandra Ochnik assisted in TMA construction, and 
Melissa Papagiris in fresh patient tissues collection 
through the Australian Prostate Cancer Bioresource. 
Oncotarget16148www.impactjournals.com/oncotarget
cONFLIcts OF INtErEst
The authors disclose no potential conflicts of 
interest.
GrANt sUPPOrt
This work was funded by the Prostate Cancer 
Foundation of Australia (GB, PG2210; RT, PG0810), 
Foundation Daw Park (SC, GG, CBP), seed funding from 
the Freemasons Foundation Centre for Men’s Health (GB), 
the US Department of Defense Prostate Cancer Research 
Program (PL, PC080010), National Health and Medical 
Research Council of Australia (RT, ID:606492), the 
National Institutes of Health (PL, 1U01CA149556-01), 
and Cancer Australia (GB, EFN, & RT, APP1032970). 
DAL holds an Australian Postgraduate Award, EFN holds 
an Early Career Fellowship from The Hospital Research 
Foundation, JH holds a National Breast Cancer Foundation 
Fellowship.
Editorial note
This paper has been accepted based in part on peer-
review conducted by another journal and the authors’ 
response and revisions as well as expedited peer-review 
in Oncotarget.
rEFErENcEs
1. American Cancer Society I. (2012). Cancer Facts & Figures 
2012. American Cancer Society).
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J 
and Zincke H. Long-term hazard of progression after radical 
prostatectomy for clinically localized prostate cancer: 
continued risk of biochemical failure after 5 years. J Urol. 
2000; 164:101-105.
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger 
M, Dorey FJ, Walsh PC and Partin AW. Risk of prostate 
cancer-specific mortality following biochemical recurrence 
after radical prostatectomy. JAMA. 2005; 294:433-439.
4. Saadi A, Shannon NB, Lao-Sirieix P, O’Donovan M, 
Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, 
Save V, Novelli M, Balkwill F and Fitzgerald RC. Stromal 
genes discriminate preinvasive from invasive disease, 
predict outcome, and highlight inflammatory pathways 
in digestive cancers. Proc Natl Acad Sci U S A. 2010; 
107:2177-2182.
5. Ma XJ, Dahiya S, Richardson E, Erlander M and Sgroi DC. 
Gene expression profiling of the tumor microenvironment 
during breast cancer progression. Breast Cancer Res. 2009; 
11:R7.
6. Brennen WN, Rosen DM, Wang H, Isaacs JT and 
Denmeade SR. Targeting carcinoma-associated fibroblasts 
within the tumor stroma with a fibroblast activation protein-
activated prodrug. J Natl Cancer Inst. 2012; 104:1320-1334.
7. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui 
RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan 
WM and Woodson KG. Gene promoter methylation in 
prostate tumor-associated stromal cells. J Natl Cancer Inst. 
2006; 98:255-261.
8. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby 
RM, Higgins SJ and Sugimura Y. The endocrinology and 
developmental biology of the prostate. Endocr Rev. 1987; 
8:338-362.
9. Chung LW, Anderson NG, Neubauer BL, Cunha GR, 
Thompson TC and Rocco AK. Tissue interactions in 
prostate development: roles of sex steroids. Prog Clin Biol 
Res. 1981; 75A:177-203.
10. Thompson TC, Cunha GR, Shannon JM and Chung LW. 
Androgen-induced biochemical responses in epithelium 
lacking androgen receptors: characterization of androgen 
receptors in the mesenchymal derivative of urogenital sinus. 
J Steroid Biochem. 1986; 25:627-634.
11. Barron DA and Rowley DR. The reactive stroma 
microenvironment and prostate cancer progression. Endocr 
Relat Cancer. 2012; 19:R187-204.
12. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea 
ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg 
M, Grummet JP, Pook DW, Stirzaker C, Clark SJ, Lawrence 
MG, Ellem SJ, et al. A bioengineered microenvironment 
to quantitatively measure the tumorigenic properties of 
cancer-associated fibroblasts in human prostate cancer. 
Biomaterials. 2013; 34:4777-4785.
13. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger 
G, Hayward SW, Wang YZ, Donjacour AA and Kurita T. 
Hormonal, cellular, and molecular regulation of normal and 
neoplastic prostatic development. J Steroid Biochem Mol 
Biol. 2004; 92:221-236.
14. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD 
and Rowley DR. Reactive stroma in human prostate cancer: 
induction of myofibroblast phenotype and extracellular 
matrix remodeling. Clin Cancer Res. 2002; 8:2912-2923.
15. Schor SL, Schor AM and Rushton G. Fibroblasts from 
cancer patients display a mixture of both foetal and adult-
like phenotypic characteristics. J Cell Sci. 1988; 90:401-
407.
16. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty 
TD and Cunha GR. Carcinoma-associated fibroblasts direct 
tumor progression of initiated human prostatic epithelium. 
Cancer Res. 1999; 59:5002-5011.
17. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, 
Jackson RS, 2nd, Revelo MP, Bhowmick NA and Hayward 
SW. Altered TGF-beta signaling in a subpopulation of 
human stromal cells promotes prostatic carcinogenesis. 
Cancer Res. 2011; 71:1272-1281.
18. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, 
Harewood L, Australian Prostate Cancer B, Collins AT, 
Oncotarget16149www.impactjournals.com/oncotarget
Maitland NJ and Risbridger GP. Human epithelial basal 
cells are cells of origin of prostate cancer, independent of 
CD133 status. Stem Cells. 2012; 30:1087-1096.
19. Bhowmick NA, Neilson EG and Moses HL. Stromal 
fibroblasts in cancer initiation and progression. Nature. 
2004; 432:332-337.
20. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, 
Shappell S, Washington MK, Neilson EG and Moses HL. 
TGF-beta signaling in fibroblasts modulates the oncogenic 
potential of adjacent epithelia. Science. 2004; 303:848-851.
21. Ao M, Franco OE, Park D, Raman D, Williams K and 
Hayward SW. Cross-talk between paracrine-acting cytokine 
and chemokine pathways promotes malignancy in benign 
human prostatic epithelium. Cancer Res. 2007; 67:4244-
4253.
22. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, 
Franco OE, Hayward SW, Cunha GR and Marker PC. 
Identification of SFRP1 as a candidate mediator of stromal-
to-epithelial signaling in prostate cancer. Cancer Res. 2005; 
65:10423-10430.
23. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, 
Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, 
Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd 
FA, Jurisica I, et al. Prognostic gene-expression signature 
of carcinoma-associated fibroblasts in non-small cell lung 
cancer. Proc Natl Acad Sci U S A. 2011; 108:7160-7165.
24. Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, 
Stehle JC and Stamenkovic I. Identification of prognostic 
molecular features in the reactive stroma of human breast 
and prostate cancer. PLoS One. 2011; 6:e18640.
25. Wikstrom P, Marusic J, Stattin P and Bergh A. Low Stroma 
Androgen Receptor Level in Normal and Tumor Prostate 
Tissue Is Related to Poor Outcome in Prostate Cancer 
Patients. Prostate. 2009; 69:799-809.
26. Cunha GR, Chung LW, Shannon JM, Taguchi O and Fujii 
H. Hormone-induced morphogenesis and growth: role of 
mesenchymal-epithelial interactions. Recent Prog Horm 
Res. 1983; 39:559-598.
27. Scher HI, Buchanan G, Gerald W, Butler LM and Tilley 
WD. Targeting the androgen receptor: improving outcomes 
for castration-resistant prostate cancer. Endocr Relat 
Cancer. 2004; 11:459-476.
28. Tindall DJ and Rittmaster RS. The rationale for inhibiting 
5alpha-reductase isoenzymes in the prevention and 
treatment of prostate cancer. J Urol. 2008; 179:1235-1242.
29. Feldman BJ and Feldman D. The development of androgen-
independent prostate cancer. Nat Rev Cancer. 2001; 1:34-
45.
30. Cunha GR and Donjacour A. Stromal-epithelial interactions 
in normal and abnormal prostatic development. Prog Clin 
Biol Res. 1987; 239:251-272.
31. Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, 
Wang Z, Tsou HC, Wei J, Walden P, Garabedian MJ and 
Lee P. Decrease in stromal androgen receptor associates 
with androgen-independent disease and promotes prostate 
cancer cell proliferation and invasion. J Cell Mol Med. 
2008; 12:2790-2798.
32. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, 
Neufing P, Stahl J, Marshall VR, Horsfall DJ and Tilley 
WD. Androgen receptor levels in prostate cancer epithelial 
and peritumoral stromal cells identify non-organ confined 
disease. Prostate. 2005; 63:19-28.
33. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky 
D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ and 
Sutherland RL. Altered expression of androgen receptor in 
the malignant epithelium and adjacent stroma is associated 
with early relapse in prostate cancer. Cancer Res. 2001; 
61:423-427.
34. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, 
Terry TR and Habib FK. Malignant transformation of 
human prostatic epithelium is associated with the loss of 
androgen receptor immunoreactivity in the surrounding 
stroma. Clin Cancer Res. 1999; 5:569-576.
35. Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden 
S, Pook DW, Frydenberg M, Papargiris MM, Niranjan 
B, Richards MG, Wang H, Collins AT, Maitland NJ and 
Risbridger GP. A preclinical xenograft model of prostate 
cancer using human tumors. Nat Protoc. 2013; 8:836-848.
36. Shang Y and Brown M. Molecular determinants for the 
tissue specificity of SERMs. Science. 2002; 295:2465-2468.
37. Gregory CW, Johnson RT, Jr., Mohler JL, French FS and 
Wilson EM. Androgen receptor stabilization in recurrent 
prostate cancer is associated with hypersensitivity to low 
androgen. Cancer Res. 2001; 61:2892-2898.
38. Santra MK, Wajapeyee N and Green MR. F-box protein 
FBXO31 mediates cyclin D1 degradation to induce G1 
arrest after DNA damage. Nature. 2009; 459:722-725.
39. Heitzer MD and DeFranco DB. Hic-5/ARA55, a LIM 
domain-containing nuclear receptor coactivator expressed 
in prostate stromal cells. Cancer Res. 2006; 66:7326-7333.
40. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba 
T, Ishino M, Takahashi S, Suzuki R and Sasaki T. Cell 
adhesion kinase beta forms a complex with a new member, 
Hic-5, of proteins localized at focal adhesions. J Biol Chem. 
1998; 273:1003-1014.
41. Leach DA, Need EF, Trotta AP, Grubisha MJ, Defranco 
DB and Buchanan G. Hic-5 influences genomic and non-
genomic actions of the androgen receptor in prostate 
myofibroblasts. Mol Cell Endocrinol. 2014; 384:185-199.
42. Palumbo A, Jr., Ferreira LB, Reis de Souza PA, Oliveira 
FL, Pontes B, Viana NB, Machado DE, Palmero CY, 
Alves LM, Gimba ER and Nasciutti LE. Extracellular 
matrix secreted by reactive stroma is a main inducer of 
pro-tumorigenic features on LNCaP prostate cancer cells. 
Cancer Lett. 2012; 321:55-64.
43. Castello-Cros R and Cukierman E. Stromagenesis during 
tumorigenesis: characterization of tumor-associated 
fibroblasts and stroma-derived 3D matrices. Methods Mol 
Oncotarget16150www.impactjournals.com/oncotarget
Biol. 2009; 522:275-305.
44. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, 
Wilkinson A, Hamdy F, Clarke N and Staffurth J. Use of 
classical and novel biomarkers as prognostic risk factors 
for localised prostate cancer: a systematic review. Health 
Technol Assess. 2009; 13:iii, xi-xiii 1-219.
45. Ehrbar M, Sala A, Lienemann P, Ranga A, Mosiewicz 
K, Bittermann A, Rizzi SC, Weber FE and Lutolf MP. 
Elucidating the role of matrix stiffness in 3D cell migration 
and remodeling. Biophys J. 2011; 100:284-293.
46. Peyton SR and Putnam AJ. Extracellular matrix rigidity 
governs smooth muscle cell motility in a biphasic fashion. 
J Cell Physiol. 2005; 204:198-209.
47. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler 
JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi 
M, Gasser DL and Weaver VM. Matrix crosslinking forces 
tumor progression by enhancing integrin signaling. Cell. 
2009; 139:891-906.
48. Kauppila S, Bode MK, Stenback F, Risteli L and Risteli 
J. Cross-linked telopeptides of type I and III collagens in 
malignant ovarian tumours in vivo. Br J Cancer. 1999; 
81:654-661.
49. Kauppila S, Stenback F, Risteli J, Jukkola A and Risteli L. 
Aberrant type I and type III collagen gene expression in 
human breast cancer in vivo. J Pathol. 1998; 186:262-268.
50. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing 
EM, Yao J, Yeh S and Chang C. Androgen receptor is a 
tumor suppressor and proliferator in prostate cancer. Proc 
Natl Acad Sci U S A. 2008; 105:12182-12187.
51. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh 
A, Marshall FF, Zhau HE and Chung LW. Soluble 
factors derived from stroma activated androgen receptor 
phosphorylation in human prostate LNCaP cells: roles of 
ERK/MAP kinase. Prostate. 2009; 69:949-955.
52. Tanner MJ, Welliver RC, Jr., Chen M, Shtutman M, Godoy 
A, Smith G, Mian BM and Buttyan R. Effects of androgen 
receptor and androgen on gene expression in prostate 
stromal fibroblasts and paracrine signaling to prostate 
cancer cells. PLoS One. 2011; 6:e16027.
53. Lai KP, Yamashita S, Huang CK, Yeh S and Chang C. Loss 
of stromal androgen receptor leads to suppressed prostate 
tumourigenesis via modulation of pro-inflammatory 
cytokines/chemokines. EMBO Mol Med. 2012; 4:791-807.
54. Ricke EA, Williams K, Lee YF, Couto S, Wang Y, 
Hayward SW, Cunha GR and Ricke WA. Androgen 
hormone action in prostatic carcinogenesis: stromal 
androgen receptors mediate prostate cancer progression, 
malignant transformation and metastasis. Carcinogenesis. 
2012;33:1391-1398.
55. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans 
KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, 
van Weerden WM and Jenster G. Androgen receptor 
modifications in prostate cancer cells upon long-
termandrogen ablation and antiandrogen treatment. Int J 
Cancer. 2005; 117:221-229.
56. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, 
Huang SP, Lardy H and Chang C. Targeting the stromal 
androgen receptor in primary prostate tumors at earlier 
stages. Proc Natl Acad Sci U S A. 2008; 105(34):12188-
12193.
57. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and 
Chung LW. Derivation of androgen-independent human 
LNCaP prostatic cancer cell sublines: role of bone stromal 
cells. Int J Cancer. 1994; 57:406-412.
58. Heitzer MD and DeFranco DB. Mechanism of action of 
Hic-5/androgen receptor activator 55, a LIM domain-
containing nuclear receptor coactivator. Mol Endocrinol. 
2006; 20:56-64.
59. Need EF, Scher HI, Peters AA, Moore NL, Cheong A, Ryan 
CJ, Wittert GA, Marshall VR, Tilley WD and Buchanan G. 
A novel androgen receptor amino terminal region reveals 
two classes of amino/carboxyl interaction-deficient variants 
with divergent capacity to activate responsive sites in 
chromatin. Endocrinology. 2009; 150:2674-2682.
60. Toivanen R, Berman DM, Wang H, Pedersen J, Frydenberg 
M, Meeker AK, Ellem SJ, Risbridger GP and Taylor RA. 
Brief report: a bioassay to identify primary human prostate 
cancer repopulating cells. Stem Cells. 2011; 29:1310-1314.
61. Trotta AP, Need EF, Butler LM, Selth LA, O’Loughlin 
MA, Coetzee GA, Tilley WD and Buchanan G. Subdomain 
structure of the co-chaperone SGTA and activity of its 
androgen receptor client. J Mol Endocrinol. 2012; 49:57-68.
62. Humphries MJ. Cell adhesion assays. Methods Mol Biol. 
2009; 522:203-210.
63. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK and 
Ricciardelli C. Versican induces a pro-metastatic ovarian 
cancer cell behavior which can be inhibited by small 
hyaluronan oligosaccharides. Clin Exp Metastasis. 2011; 
28:113-125.
